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Because of its still rising incidence and high mortality rate in intensive care unit (ICU) patients, early recognition of
acute kidney injury (AKI) remains a critical issue. Surprisingly, effective biomarkers for early detection and hence
appropriate and timely therapy of AKI have not yet entered the clinical arena. We performed a systematic search of
the literature published between 1999 and 2011 on potential early biomarkers for acute renal failure/kidney injury
in an at-risk adult and pediatric population following the Quorum Guidelines. Based on this review,
recommendations for the clinical use of these biomarkers were proposed. In general, kidney biomarkers may aid to
direct early aggressive treatment strategies for AKI thereby decreasing the associated high mortality. To date,
however, sensitivity and specificity of individual biomarker assays are low and do not sustain their routine clinical
use. “Kits” containing a combination of established biomarkers, in conjunction with measured glomerular filtration
rate, may enhance diagnostic and prognostic accuracy in the future.
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Introduction
Accurate diagnosis of AKI in an ICU setting is challen-
ging. Indeed, the characteristic swings in renal function
over time in critically ill patients largely reduce the val-
idity of a sole creatinine-based AKI assessment. This has
stimulated researchers to establish multidimensional
classification systems that use specific criteria to grade
AKI severity. At present, the RIFLE classification repre-
sents the most widely accepted tool to “score” AKI
severity.
To better discriminate for AKI severity, early recogni-
tion of renal dysfunction, i.e., well before changes in
serum creatinine do occur, has gained considerable
interest. It has been evidenced that small or relative
increases in serum creatinine are associated with a con-
comitant increase in patient mortality. However, even
serial evaluation of serum creatinine levels does not* Correspondence: Patrick.Honore@uzbrussel.be
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in any medium, provided the original work is pallow to intercept adequately the rapidly evolving
changes in renal function in severely ill subjects. There-
fore, attention has focused on the development of “early”
biomarkers, enabling diagnosis of AKI long before cre-
atinine levels start to increase. Logically, a combination
of biomarkers could enhance diagnostic accuracy, but
validation of current individual candidate biomarkers is
still underway.Looking for the “kidney troponin”
The intensive care community is faced with an import-
ant and frustrating dilemma. On the one hand, AKI is
increasingly complicating the course of disease in critic-
ally ill patients causing several million deaths worldwide
every year [1]. On the other hand, despite being aware
of the AKI burden on outcome, ICU physicians remain
deprived of effective biomarkers for early recognition of
AKI. As a consequence, the delay in initiating appropri-
ate therapy contributes significantly to the dismal prog-
nosis of AKI [2].
In contrast with the variety of biological markers (in-
cluding troponins) for early diagnosis of cardiac damage
[3], standard assessment of renal function in ICUan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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atinine levels and serum creatinine-based formulas [4].
However, while being designed primarily for longitudinal
assessment of baseline renal function and validated
merely in chronic kidney failure, creatinine-based
decision-making in critically ill patients is debatable
[4,5]. Accurate diagnosis of AKI becomes problematic
when renal homeostasis is considerably influenced by
rapidly evolving circulatory and inflammatory altera-
tions. Under such conditions, the value of “classical”
measures of renal function becomes doubtful.
Many studies have emphasized the role of AKI as an
independent risk factor for mortality in the critically ill,
causing patients to die from and not just “with” AKI
[5,6]. This has stimulated the development of multidi-
mensional AKI classification systems. Such classifica-
tions provide a more accurate description of AKI, allow
AKI severity grading, and better predict outcome. At
present, the most widely used classification is the
RIFLE—an acronym for Risk, Injury, Failure, Loss, and
End-stage renal disease—system, which was initially pro-
posed by the Acute Dialysis Quality Initiative group [7]
and has been validated in critically ill adult patients [8].
ICU patients with maximum RIFLE class R, I and F had
hospital mortality rates of respectively 8.8%, 11.4%, and
26.3% [8].
It has been recently appreciated that vital body organs
share information by virtue of various biological media-
tors. As a consequence, a pathology affecting one major
organ can cause dysfunction of another apparently unre-
lated organ. The so-called cardiorenal syndrome, where
primary dysfunction of the heart can cause kidney injury
and vice versa, is a striking example of such organ cross-
talk in critically ill patients. Because cellular injury
occurs before clinical dysfunction, the potential of bio-
logical markers to detect subclinical molecular changes
may render therapeutic interventions more effective. Ex-
tensive research is performed to find biomarker sub-
stances present in urine or serum, imaging techniques,
or any other quantifiable parameters to detect—either
alone or in combination—both heart and kidney dys-
function. Results of these investigations are still
awaited [9].
Why biomarkers should be preferred to creatinine: the
mortality issue
Small or relative increases in serum creatinine are asso-
ciated with increased patient morbidity and mortality
independently of expected mortality as calculated by
mortality risk scores. Chertow and colleagues found a
nearly sevenfold increase in the odds of death for
patients presenting a 0.5 mg/dL increase in serum cre-
atinine, even when adjusted for numerous comorbidities
[6]. As stated previously, serum creatinine concentrationsas well as creatinine clearance are unreliable indicators of
acute or abrupt changes in kidney function in ICU
patients [10]. Serum creatinine comes into play as a mar-
ker for decreasing kidney function when already more
than 50% of kidney function has been lost and is only
useful after a steady state has been reached. The latter
can take time (sometimes up to 48 h), especially in ICU
patients [11]. Creatinine clearance is a better marker for
changes in kidney function, although again with consid-
erable delay because of the time lag between cellular kid-
ney damage and loss of kidney function [12]. Studies in
humans have shown that AKI can be prevented or more
adequately contained if treatment is instituted shortly
after the initial kidney insult [13]. This underscores the
need for a biomarker to early detect kidney injury in the
ICU [14].
Apart from allowing a more early diagnosis of kidney
damage, biomarkers also may be used to better differenti-
ate the etiology of AKI, resulting in more appropriate or
adjusted treatment [15]. The potential benefits of such ap-
proach are immense as the presence of AKI enhances the
intrinsic mortality caused by the initial and/or underlying
disease [16,17]. Furthermore, epidemiologic studies have
shown that half of the cases of AKI in the ICU are related
to sepsis, with a superimposed mortality that is higher
than in nonseptic AKI [18].
Assessing specificity and sensitivity of biomarkers using
creatinine-based criteria: a flawed paradigm?
Diagnostic specificity and sensitivity of biomarkers are
currently weighed against creatinine-based criteria. Such
comparative relationship is questionable, because creatin-
ine itself is a rather poor biomarker of renal function. As a
consequence, increased levels of one specific biomarker in
the presence of normal creatinine values may point to true
renal injury (which creatinine fails to detect) or be falsely
positive. As outlined by Waikar et al. [19], creatinine levels
by no means reliably reflect renal function. Creatinine def-
initely is no marker of kidney injury and merely a surro-
gate for evaluation of renal function . In the acute critical
care setting, the role of creatinine as a marker of kidney
injury may even be more criticized. For example, the syn-
drome “pre-renal azotaemia” may biochemically (i.e., by
changes in creatinine concentrations) resemble “acute
tubular necrosis.” However, the underlying pathophysi-
ology, treatment implications and prognosis of these dis-
orders are markedly different. Intensive care physicians
familiar with AKI know that creatinine can be deceptively
normal when kidneys are failing [19]. In a sense, we are
on the verge of a potential paradigm shift in critical care
nephrology, where creatinine may be replaced by novel
biomarkers for diagnosis of tubular injury. Various bio-
logically plausible biomarkers have indeed been identified
in animal models and, even if potentially imperfect, await
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diagnosis of AKI in critically ill patients will be freed from
the creatinine “stigma” in the way that diagnosis of myo-
cardial infarction exchanged measurement of lactate de-
hydrogenase and creatine phosphokinase for the highly
specific troponin recording.
Potential biomarker candidates
Actually, more than ten promising biomarkers for AKI
have been identified. The most relevant substances are
neutrophil gelatinase-associated lipocalin (NGAL) [21],
cystatin C [22], kidney injury molecule-1 (KIM-1) [23],
beta-2 microglobulin (β2M) [24], and interleukin-18 (IL-
18) [25].
NGAL is a 25-kDa protein bound to gelatinase from
neutrophils [26]. In animal models, NGAL appears im-
mediately after induction of an ischemic or nephrotoxic
insult [26,27]. Devarajan and coworkers recently com-
pleted remarkable downstream proteomic analyses on
NGAL [28]. Preclinical transcriptome profiling studies in
acutely injured animals identified the NGAL gene as one
of the most and very early upregulated ones expressed in
the kidney [29]. Additional analyses in animals con-
firmed that NGAL was amongst the most intensely
induced proteins in the kidney after ischemic or nephro-
toxic injury [30].
Plasma and urinary NGAL have shown promise as
early biomarkers of clinical AKI in cardiopulmonary by-
pass surgery, kidney transplantation, following intraven-
ous contrast administration, and in ICU patients [25–
29]. NGAL measurement has been employed as an out-
come variable in clinical trials that investigated the effect
of hydroxyethylstarch infusion over other colloids on
maintaining renal function in elderly cardiac surgery
patients [31–33]. Also, an attenuated response of urinary
NGAL was found in adult cardiac surgery patients in
whom a lower incidence of AKI was noted when sodium
bicarbonate was administered instead of sodium chloride
[34]. Notwithstanding these promising results, the num-
ber of patients studied remains small and a large, pro-
spective, multicentric study is needed to delineate the
exact role and potential of NGAL [28,35].
Cystatin C is a protease inhibitor that is released into
the blood, filtered through the glomerulus, and com-
pletely reabsorbed in the proximal tubule. In chronic
kidney disease, cystatin C was found to better predict
glomerular function than serum creatinine [36]. In car-
diac surgery patients, a 50% increase in cystatin C could
predict AKI 48 h before changes in serum creatinine or
creatinine clearance suggested renal dysfunction [37]. In
practice, however, NGAL is still an earlier biomarker
than cystatin C [37].
KIM-1 was identified as a transmembrane protein pro-
duced by the proximal tubule following ischemic ortoxin-induced AKI [23]. KIM-1 is measured in the urine.
It has been thoroughly investigated in patients undergo-
ing cardiopulmonary bypass where it proved to be more
specific than NGAL in detecting ischemic and nephro-
toxic AKI [23]. In this particular setting, KIM-1 adds
specificity whilst NGAL proved to be more sensitive.
Cystatin C, while also being a very sensitive marker, was
less specific as compared to KIM-1 and NGAL [5,38].
β2 -microglobulins are low-molecular-weight proteins
freely filtered by the glomerulus [39]. Unlike creatinine,
their serum concentrations are less dependent on extra-
renal factors [39]. In a recent cross-sectional analysis,
Herrero-Morin and coworkers showed that cystatin C
and β2M was found to be largely superior to a creatinine
clearance cutoff<80 mL/min/1.73 m2 for detecting
decreased glomerular filtration rate in critically ill chil-
dren [24].
IL-18 is a proinflammatory cytokine that is produced
at the proximal tubular level. IL-18 has been identified
as a very early biomarker of AKI in kidney transplant
patients, acute respiratory distress syndrome, and after
cardiopulmonary bypass surgery [40].
A major drawback limiting the routine use of biomar-
kers is their low individual sensitivity and specificity,
generally not exceeding 70–75%, for detecting early kid-
ney damage [41]. One possible solution might be the
creation of a kit incorporating various biomarkers to
allow quick and accurate diagnosis of AKI while patients
are still in the ICU [5,42,43]. As therapy (e.g., CVVH)
may then not only be started more early but also
becomes tailored to the type of AKI, a huge impact on
outcome might be expected [44].
Synergy between biomarkers and serum creatinine
The potential synergy of concomitant use of biomarkers
and serum creatinine-derived measurement of glomerular
filtration rate (GFR) must be underlined. In a recent study,
NGAL and serum creatinine-derived GFR, measured at
ICU admission, both predicted development of severe
AKI. However, the combination of NGAL and GFR as-
sessment significantly increased predictive accuracy. Inter-
estingly, in the presence of normal serum creatinine
values, NGAL alone remained predictive for AKI [45].
Conclusions and recommendations
Early diagnosis of AKI, particularly in severely ill
patients, remains difficult. Creatinine-based measure-
ments prove to be little helpful. Serum creatinine levels
start to increase when most of the kidney function is
already lost and a steady state has been reached. Creatin-
ine clearance also remains a late and indirect marker of
AKI [46–48].
Currently, much attention goes to biomarkers that are
able to detect AKI in an earlier phase of development.
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IL-18. Apart from a role in diagnosis, some markers (e.
g., NGAL) also may have benefit in assessing eventual
unwarranted renal effects of toxins, ischemic events, and
infusion fluids. Validation of those kidney markers in
various conditions of AKI is actually ongoing [47,48].
However, clinical studies on biomarkers are still scarce,
particularly in critically ill patients, and sensitivity and
specificity of individual biomarkers remain unacceptably
low [48]. Development of biomarker kits that combine
markers with different characteristics may increase diag-
nostic accuracy. Large multicentric randomized studies
are imperative to confirm whether the use of biomarkers
can influence course and treatment of AKI [49,50]. Fi-
nally, linking the assessment of biomarker specificity
and sensitivity to creatinine-based criteria should be
abandoned. An early and goal-directed therapy for AKI
by using offensive strategies that are “covered” and
directed by early and serial evaluation of biomarkers
probably is the ultimate method to combat excessive
“renal” mortality in the ICU.
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